193 related articles for article (PubMed ID: 35483882)
21. CCNB2 and AURKA overexpression may cause atypical mitosis in Japanese cortisol-producing adrenocortical carcinoma with TP53 somatic variant.
Ikeya A; Nakashima M; Yamashita M; Kakizawa K; Okawa Y; Saitsu H; Sasaki S; Sasano H; Suda T; Oki Y
PLoS One; 2020; 15(4):e0231665. PubMed ID: 32287321
[TBL] [Abstract][Full Text] [Related]
22. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.
Wasserman JD; Novokmet A; Eichler-Jonsson C; Ribeiro RC; Rodriguez-Galindo C; Zambetti GP; Malkin D
J Clin Oncol; 2015 Feb; 33(6):602-9. PubMed ID: 25584008
[TBL] [Abstract][Full Text] [Related]
23. Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas.
Ye J; Qi Y; Wang W; Sun F; Wei Q; Su T; Zhou W; Jiang Y; Yuan W; Cai J; Cui B; Ning G
Endocrine; 2012 Jun; 41(3):479-86. PubMed ID: 22311173
[TBL] [Abstract][Full Text] [Related]
24. ENDOCRINE TUMOURS: The genomics of adrenocortical tumors.
Faillot S; Assie G
Eur J Endocrinol; 2016 Jun; 174(6):R249-65. PubMed ID: 26739091
[TBL] [Abstract][Full Text] [Related]
25. Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immunohistochemical, and targeted next-generation sequencing analysis.
Papathomas TG; Duregon E; Korpershoek E; Restuccia DF; van Marion R; Cappellesso R; Sturm N; Rossi G; Coli A; Zucchini N; Stoop H; Oosterhuis W; Ventura L; Volante M; Fassina A; Dinjens WN; Papotti M; de Krijger RR
Hum Pathol; 2016 Dec; 58():113-122. PubMed ID: 27589897
[TBL] [Abstract][Full Text] [Related]
26. Development and Validation of an m6A RNA Methylation Regulators-Based Signature for Predicting the Prognosis of Adrenocortical Carcinoma.
Shen C; Liu J; Yang X; Jiao W; Wang Y
Front Endocrinol (Lausanne); 2021; 12():568397. PubMed ID: 33692753
[TBL] [Abstract][Full Text] [Related]
27. Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers.
Gaujoux S; Pinson S; Gimenez-Roqueplo AP; Amar L; Ragazzon B; Launay P; Meatchi T; Libé R; Bertagna X; Audebourg A; Zucman-Rossi J; Tissier F; Bertherat J
Clin Cancer Res; 2010 Nov; 16(21):5133-41. PubMed ID: 20978149
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma.
Korah R; Healy JM; Kunstman JW; Fonseca AL; Ameri AH; Prasad ML; Carling T
Mol Cancer; 2013 Aug; 12():87. PubMed ID: 23915220
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors.
Fonseca AL; Kugelberg J; Starker LF; Scholl U; Choi M; Hellman P; Åkerström G; Westin G; Lifton RP; Björklund P; Carling T
Genes Chromosomes Cancer; 2012 Oct; 51(10):949-60. PubMed ID: 22733721
[TBL] [Abstract][Full Text] [Related]
30. Genetics of tumors of the adrenal cortex.
Bonnet-Serrano F; Bertherat J
Endocr Relat Cancer; 2018 Mar; 25(3):R131-R152. PubMed ID: 29233839
[TBL] [Abstract][Full Text] [Related]
31. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers.
Ragazzon B; Libé R; Gaujoux S; Assié G; Fratticci A; Launay P; Clauser E; Bertagna X; Tissier F; de Reyniès A; Bertherat J
Cancer Res; 2010 Nov; 70(21):8276-81. PubMed ID: 20959480
[TBL] [Abstract][Full Text] [Related]
32. TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma.
Svahn F; Paulsson JO; Stenman A; Fotouhi O; Mu N; Murtha TD; Korah R; Carling T; Bäckdahl M; Wang N; Juhlin CC; Larsson C
Int J Mol Med; 2018 Sep; 42(3):1675-1683. PubMed ID: 29956721
[TBL] [Abstract][Full Text] [Related]
33. Inhibin alpha-subunit (INHA) expression in adrenocortical cancer is linked to genetic and epigenetic INHA promoter variation.
Hofland J; Steenbergen J; Voorsluijs JM; Verbiest MM; de Krijger RR; Hofland LJ; de Herder WW; Uitterlinden AG; Feelders RA; de Jong FH
PLoS One; 2014; 9(8):e104944. PubMed ID: 25111790
[TBL] [Abstract][Full Text] [Related]
34. Objective assessment of adrenocortical carcinoma driver genes and their correlation with tumor pyruvate kinase M2.
Das R; Ghosh Chowdhury M; Raundal S; Jadhav J; Kumar N; Patel S; Shard A
Gene; 2022 May; 822():146354. PubMed ID: 35189247
[TBL] [Abstract][Full Text] [Related]
35. Establishing a human adrenocortical carcinoma (ACC)-specific gene mutation signature.
Rahane CS; Kutzner A; Heese K
Cancer Genet; 2019 Jan; 230():1-12. PubMed ID: 30477734
[TBL] [Abstract][Full Text] [Related]
36. Molecular genomic profiling of adrenocortical cancers in clinical practice.
Darabi S; Braxton DR; Eisenberg BL; Demeure MJ
Surgery; 2021 Jan; 169(1):138-144. PubMed ID: 32709489
[TBL] [Abstract][Full Text] [Related]
37. Pathogenesis of adrenocortical cancer.
Bertherat J; Bertagna X
Best Pract Res Clin Endocrinol Metab; 2009 Apr; 23(2):261-71. PubMed ID: 19500768
[TBL] [Abstract][Full Text] [Related]
38. Combined steroidogenic characters of fetal adrenal and Leydig cells in childhood adrenocortical carcinoma.
Fujisawa Y; Sakaguchi K; Ono H; Yamaguchi R; Kato F; Kagami M; Fukami M; Ogata T
J Steroid Biochem Mol Biol; 2016 May; 159():86-93. PubMed ID: 26940356
[TBL] [Abstract][Full Text] [Related]
39. AXIN genetic analysis in adrenocortical carcinomas updated.
Guimier A; Ragazzon B; Assié G; Tissier F; Dousset B; Bertherat J; Gaujoux S
J Endocrinol Invest; 2013 Dec; 36(11):1000-3. PubMed ID: 23812285
[TBL] [Abstract][Full Text] [Related]
40. Elucidation of the Genomic-Epigenomic Interaction Landscape of Aggressive Prostate Cancer.
Kumar Mamidi TK; Wu J; Hicks C
Biomed Res Int; 2021; 2021():6641429. PubMed ID: 33511206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
